Skip to main content
SpringerLink
Log in

Das Hodgkin-Lymphom beim alten und geriatrischen Patienten

  • Chapter
  • First Online:
Geriatrische Onkologie

Part of the book series: Springer Reference Medizin ((SRM))

  • 1615 Accesses

Zusammenfassung

Sofern Komorbidität eine Polychemotherapie nicht verbietet, ist auch bei älteren Hodgkin Patienten in allen Stadien eine Therapie mit kurativem Ziel möglich. In frühen Stadien sind zwei Zyklen ABVD + 20Gy IF-RT meist durchführbar und effektiv. Bei Patienten im intermediären Stadium führt eine Behandlung mit dem Standard vier Zyklen ABVD + 30Gy IF-RT zu einer deutlich erhöhte Rate an Toxizität. Dies gilt umso mehr bei den Patienten in fortgeschrittenen Stadien. Diese erhalten sechs bis acht Zyklen einer Polychemotherapie, wobei bisher kein alternatives Regime gegenüber A(B)VD überlegen ist. Auf Bleomycin muss wegen pulmonaler Toxizität oft teilweise oder ganz verzichtet werden. Unklar ist, welche Patienten palliativ behandelt werden sollten und die Wahl der richtigen Rezidivtherapie. Aktuell werden neue Substanzen wie Brentuximab vedotin oder Checkpoint-Inhibitoren als weniger toxische und wirksame Therapieoption bei älteren Patienten geprüft.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 159.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Ballova V et al (2005) A prospectively randomized trial carried out by the German Hodgkin study group (GHSG) for elderly patients with advanced Hodgkin’s disease comparing BEACOPP baseline and COPP-ABVD (studyHD9elderly). Ann Oncol 16(1):124–131

    Google Scholar 

  • Behringer K et al (2014) Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin’s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet 2015, Apr 11 385(9976), S 1–10

    Google Scholar 

  • Björkholm M, Svedmyr E, Sjöberg J (2011) How we treat elderly patients with Hodgkin lymphoma. Curr Opin Oncol 23(5):421–428

    Article  PubMed  Google Scholar 

  • Boell B et al (2013) German Hodgkin Study Group phase I trial of doxorubicin, vinblastine, dacarbazine, and lenalidomide (AVD-Rev) for older Hodgkin lymphoma patients. Blood 122(21)

    Google Scholar 

  • Böll B et al (2011) Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood 118(24):6292–6298

    Article  PubMed  Google Scholar 

  • Böll B, Görgen H, Fuchs M et al (2013a) ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin study group HD10 and HD11 trials. J Clin Oncol 31(12):1522–1529

    Article  PubMed  Google Scholar 

  • Böll B, Goergen H, Arndt N et al (2013b) Relapsed Hodgkin lymphoma in older patients: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 31(35):4431–4437

    Article  PubMed  Google Scholar 

  • Böll B et al (2016) Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood 127(18):2189–2192

    Article  PubMed  Google Scholar 

  • Canellos GP et al (2004) How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen? J Clin Oncol 22(8):1532–1533

    Article  PubMed  Google Scholar 

  • Diehl V et al (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med 348(24):2386–2395

    Article  CAS  PubMed  Google Scholar 

  • Eich HT et al (2010) Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin study group HD11 trial. J Clin Oncol 28(27):4199–4206

    Article  PubMed  Google Scholar 

  • Eichenauer DA et al (2014) Hodgkin’s lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii70–iii75

    Article  PubMed  Google Scholar 

  • Elias R et al (2016) Immune checkpoint inhibitors in older adults. Curr Oncol Rep. 2016 Aug;18(8):47. S 1–7

    Google Scholar 

  • Engert A et al (2009) Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 27(27):4548–4554

    Article  PubMed  Google Scholar 

  • Engert A et al (2010) Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 363(7):640–652

    Article  CAS  PubMed  Google Scholar 

  • Engert A et al (2012) Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet May 12;379(9828):1791–1799

    Google Scholar 

  • Evens AM, Hong F (2013) How can outcomes be improved for older patients with Hodgkin lymphoma? J Clin Oncol 2013 Apr 20 31(12):1502–1505

    Google Scholar 

  • Evens AM et al (2012) A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood 119(3):692–695

    Article  CAS  PubMed  Google Scholar 

  • Evens AM et al (2013) The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol 161(1):76–86

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Forero-Torres A et al (2015) Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood 126(26):2798–2804

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Halbsguth TV et al (2010) Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin study group (GHSG). Blood 116(12):2026–2032

    Article  CAS  PubMed  Google Scholar 

  • Halbsguth TV et al (2011) The unique characteristics and management of patients over 60 years of age with classic Hodgkin lymphoma. Curr Hematol Malig Rep 6(3):164–171

    Article  PubMed  Google Scholar 

  • Jezeršek Novaković B (2016) Checkpoint inhibitors in Hodgkin’s lymphoma. Eur J Haematol 96(4):335–343

    Article  PubMed  Google Scholar 

  • Josting A (2005) Salvage radiotherapy in patients with relapsed and refractory Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol 23(7):1522–1529

    Article  PubMed  Google Scholar 

  • Josting A et al (2002) New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 20(1):221–230

    PubMed  Google Scholar 

  • Kolstad A et al (2007) Standard CHOP-21 as first line therapy for elderly patients with Hodgkin’s lymphoma. Leuk Lymphoma 48(3):570–576

    Article  CAS  PubMed  Google Scholar 

  • Landgren O et al (2003) Hodgkin’s lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica 88(4):438–444

    PubMed  Google Scholar 

  • Levis A et al (2004) VEPEMB in elderly Hodgkin’s lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. Ann Oncol 15(1):123–128

    Article  CAS  PubMed  Google Scholar 

  • Levis A et al (2007) ABVD versus VEPEMB in elderly Hodgkin’s lymphoma patients. Blood 110(11):2322

    Google Scholar 

  • Martin WG (2005) Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol 23(30):7614–7620

    Article  CAS  PubMed  Google Scholar 

  • Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012 Mar 22;12(4):252–264. S 1–13

    Google Scholar 

  • Proctor SJ, Wilkinson J (2007) A web-based study concept designed to progress clinical research for „orphan“ disease areas in haematological oncology in the elderly: the SHIELD programme. Crit Rev Oncol Hematol 61(1):79–83

    Article  CAS  PubMed  Google Scholar 

  • Proctor SJ et al (2002) Hodgkin’s disease in the elderly: current status and future directions. Ann Oncol 13(Suppl 1):133–137

    Article  PubMed  Google Scholar 

  • Proctor SJ et al (2012) Prospective evaluation of treatment outcome in 175 patients with Hodgkin lymphoma (HL) aged sixty years or over: the SHIELD study. Blood 119(25):6005–6015

    Article  CAS  PubMed  Google Scholar 

  • Puig N et al (2011) High-dose chemotherapy and auto-SCT in elderly patients with Hodgkin’s lymphoma. BMT 46(10):1339–1344

    CAS  Google Scholar 

  • Radford J et al (2015) Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med 372(17):1598–1607

    Article  CAS  PubMed  Google Scholar 

  • Raemaekers JMM et al (2014) Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 32(12):1188–1194

    Article  PubMed  Google Scholar 

  • Santoro A et al (2000) Gemcitabine in the treatment of refractory Hodgkin’s disease: results of a multicenter phase II study. J Clin Oncol 18(13):2615–2619

    Article  CAS  PubMed  Google Scholar 

  • Sjöberg J et al (2012) Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973–2009. Blood 119(4)

    Google Scholar 

  • Stamatoullas A et al (2015) Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol 170(2):179–184

    Article  CAS  PubMed  Google Scholar 

  • Tresckow B von et al (2012) Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin study group HD14 trial. J Clin Oncol 30(9):907–913

    Google Scholar 

  • Weekes CD et al (2002) Hodgkin’s disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen. J Clin Oncol 20(4):1087–1093

    CAS  PubMed  Google Scholar 

  • Younes A et al (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 30(18):2183–2189

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zallio F et al (2016) Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL). Br J Haematol 172(6):879–888

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Deutsche Hodgkin Studiengruppe (GHSG) Klinik I für Innere Medizin-Hämatologie-Onkologie, Internistische Intensivmedizin, Kerpener Strasse 62, 50937, Köln, Deutschland

    Boris Böll

Authors
  1. Boris Böll
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Boris Böll .

Editor information

Editors and Affiliations

  1. II. Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim, Germany

    Matthias Ebert

  2. II. Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim, Germany

    Nicolai Härtel

  3. Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany

    Ulrich Wedding

Section Editor information

  1. Abteilung für Palliativmedizin, Universitätsklinikum Jena, Klinik für Innere Medizin II, Erlanger Allee 101, 07747, Jena, Deutschland

    Ulrich Wedding

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Böll, B. (2018). Das Hodgkin-Lymphom beim alten und geriatrischen Patienten. In: Ebert, M., Härtel, N., Wedding, U. (eds) Geriatrische Onkologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-48727-3_22

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-48727-3_22

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-48726-6

  • Online ISBN: 978-3-662-48727-3

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation